Santen Ventures co-led a series B round also backed by C-Mer Eye Care and BioLight Life Science to bring Belkin Laser's funding total to $16.3m.
Israel-based glaucoma laser treatment developer Belkin Laser has closed a $12.3m series B round co-led by Santen Ventures, the corporate venturing fund for pharmaceuticals firm Santen.
The round was co-led by Rimonci Capital and also included eye care product developer BioLight Life Science, ophthalmological holding company C-Mer Eye Care and CR-CP Life Science Fund, a joint venture of conglomerates China Resources and Charoen Pokphand.
Founded in 2013, Belkin Laser is working on a non-invasive laser treatment for glaucoma to supplant…
